Melanoma: baseline predictors of dabrafenib + trametinib efficacy
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Pooled analysis using the largest data set available for BRAF and MEK inhibitor combination treatment in melanoma identified patient and clinical factors that can help predict outcomes with dabrafenib (Tafinlar) plus trametinib (Mekinist) treatment.
Why this matters
The findings can help provide a framework for further exploring melanoma drug resistance mechanisms and prolonged patient response and survival, which could play an important role in developing new treatments.
Retrospective individual data analysis using all published randomized trials that included treatment-naive patients with BRAFV600E-mutant or BRAFV600K-mutant metastatic melanoma who received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily.